alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
I 

118TH CONGRESS 

1ST SESSION H. R. 1470 

To prohibit the use of Federal funds for abortion through financial or 

logistical support to individuals traveling to another State or country 

to receive an abortion. 

IN THE HOUSE OF REPRESENTATIVES 

MARCH 8, 2023 

Mr. NORMAN (for himself, Mr. BANKS, Mrs. BOEBERT, Mr. CLOUD, Mr. DAVIDSON, Mr. DUNCAN, Mr. ELLZEY, Mr. GOOD of Virginia, Mr. GOSAR, 

Ms. GREENE of Georgia, Mr. GROTHMAN, Mr. HERN, Mr. KELLY of Mississippi, Mrs. MILLER of Illinois, Mr. OGLES, Mr. ROSENDALE, Mr. SESSIONS, Mr. STEUBE, Mr. WALTZ, Mr. WESTERMAN, and Mr. LAMBORN) 

introduced the following bill; which was referred to the Committee on Energy and Commerce 

A BILL 

To prohibit the use of Federal funds for abortion through 

financial or logistical support to individuals traveling to 

another State or country to receive an abortion. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘No Federal Funds for 

5 Abortion Travel Expenses Act of 2023’’. 


pbinns on DSKJLVW7X2PROD with $$_JOB
2 

•HR 1470 IH

1 SEC. 2. NO FEDERAL FUNDS FOR ABORTION TRAVEL. 

2 (a) IN GENERAL.—No Federal funds may be used 

3 for abortion through financial or logistical support for 

4 travel to another State for an abortion. 

5 (b) RULE OF CONSTRUCTION.—Nothing in this sec6 tion shall be construed to affect the limits on funding for 

7 abortion through financial or logistical support for travel 

8 to another State or country to receive an abortion in effect 

9 under the Hyde Amendment or any other provision of 

10 Federal law. 

11 (c) DEFINITIONS.—In this section: 

12 (1) The term ‘‘abortion’’ means the use or pro13 vision of any instrument, medicine, drug, or any 

14 other substance or device— 

15 (A) to intentionally kill the unborn child of 

16 a woman known to be pregnant; or 

17 (B) to intentionally terminate the preg18 nancy of a woman known to be pregnant, with 

19 an intention other than— 

20 (i) after viability to produce a live 

21 birth that, if premature, is medically indi22 cated, and to preserve the life and health 

23 of the child born alive; 

24 (ii) to treat an ectopic pregnancy; or 

25 (iii) to remove a dead unborn child. 


pbinns on DSKJLVW7X2PROD with $$_JOB
3 

•HR 1470 IH

1 (2) The term ‘‘Hyde Amendment’’ means sec2 tions 506 and 507 of division H of the Consolidated 

3 Appropriations Act, 2022 (Public Law 117–103) 

4 and any successor provisions in any appropriations 

5 Act for a fiscal year after fiscal year 2022. 

Æ 


pbinns on DSKJLVW7X2PROD with $$_JOB
Exhibit 10.44**AMENDMENT NO. 1 TO ESCROW AGREEMENT**     This Amendment No. 1 to Escrow Agreement is made this 10th day of August, 2007, byand among AMDL, Inc., a Delaware corporation (“Buyer”), Jade Capital Group Limited, a BritishVirgin Islands corporation (“Jade Capital”), Pearl King Global Limited (“Pearl King”), and HomingNominees Limited (“Homing”) (collectively Pearl King and Homing are referred to as “Shareholders”)and Louis Taubman, Esquire (in his capacity as Escrow Holder hereunder, the “Escrow Holder”).**RECITALS**     This Amendment is being entered into in reference to the following facts:     A. During the period after the execution of the Escrow Agreement dated as of September 28,2007 (“Escrow Agreement”) and the date hereof, the China State Federal Drug Agency (“SFDA”) hadundergone significant changes in administration, including but not limited to, the death byexecution of the chairman of the SFDA, none of which changes could have been reasonably anticipatedby the parties to the Escrow Agreement at the time of execution thereof.     B. Both Buyer and Jade Capital have proceeded diligently with the preparation and filing ofthe SFDA application for approval of DR-70®, but some of the delays were attributable toBuyer.     C. In fairness to Jade Capital and its stockholders, Buyer has agreed to extend the date forreceipt of SFDA approval of DR-70®to March 28, 2008.     NOW, THEREFORE, it is agreed as follows:     1. Article 2 of the Escrow Agreement is amended and restated to read in full as follows:“ARTICLE 2 — THE ESCROW     The Escrow Holder shall disburse the Escrow Shares in accordance with thefollowing procedures:     (a) If, before March 28, 2007, Jade Capital and/or the Shareholders shallhave demonstrated that People’s Republic of China State Federal Drug Agency orother appropriate agency (“SFDA”) has issued a permit or the equivalent regulatoryapproval for Buyer to sell and distribute DR-70® in the People’s Republic of Chinawithout qualification (the “Approval to Market DR-70®”), in form and substancesatisfactory to Buyer, then the Escrow Holder shall promptly disburse the EscrowShares to Jade Capital and/or Shareholders, in such proportions as Jade Capitalshall instruct.
 

 
     (b) If Jade Capital has not notified Escrow Holder that the SFDA has issuedthe Approval to Market DR-70® before March 28, 2008, or if Buyer disputes that thepurported approval is satisfactory, the Escrow Shares shall be delivered by EscrowHolder to Buyer for cancellation.”     2. All other provisions of the Escrow Agreement shall remain unchanged by this Amendment No.1.     IN WITNESS WHEREOF, the parties have caused this Agreement to be duly executed as of the dateand year first above written.
      **“BUYER”**
**EXHIBIT 31.2**

I, JohnC. Pintozzi, certify that:

1. Ihave reviewed this quarterly report on Form 10-Q of Allstate Life InsuranceCompany of New York;

2. Based on my knowledge, this report does not containany untrue statement of a material fact or omit to state a material factnecessary to make the statements made, in light of the circumstances underwhich such statements were made, not misleading with respect to the periodcovered by this report;

3. Based on my knowledge, the financial statements,and other financial information included in this report, fairly present in allmaterial respects the financial condition, results of operations and cash flowsof the registrant as of, and for, the periods presented in this report;

4. The registrant’s othercertifying officer(s) and I are responsible for establishing and maintainingdisclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)and 15d-15(e)) for the registrant and have:

a)                 Designedsuch disclosure controls and procedures, or caused such disclosure controls andprocedures to be designed under our supervision, to ensure that materialinformation relating to the registrant, including its consolidatedsubsidiaries, is made known to us by others within those entities, particularlyduring the period in which this report is being prepared;

b)                Evaluatedthe effectiveness of the registrant’s disclosure controls and procedures andpresented in this report our conclusions about the effectiveness of thedisclosure controls and procedures, as of the end of the period covered by thisreport based on such evaluation; and

c)                 Disclosedin this report any change in the registrant’s internal control over financialreporting that occurred during the registrant’s most recent fiscal quarter (theregistrant’s fourth fiscal quarter in the case of an annual report) that hasmaterially affected, or is reasonably likely to materially affect, theregistrant’s internal control over financial reporting; and

5. The registrant’s othercertifying officer(s) and I have disclosed, based on our most recent evaluationof internal control over financial reporting, to the registrant’s auditors andthe audit committee of registrant’s board of directors (or persons performingthe equivalent functions):

a)                 Allsignificant deficiencies and material weaknesses in the design or operation ofinternal control over financial reporting which are reasonably likely toadversely affect the registrant’s ability to record, process, summarize andreport financial information; and

b)                Anyfraud, whether or not material, that involves management or other employees whohave a significant role in the registrant’s internal control over financialreporting.

August 8, 2006
|        |   | /s/ John C. Pintozzi                                                   |
|--------|--------|------------------------------------------------------------------------|
|   |   | John C. Pintozzi   Senior Vice President and   Chief Financial Officer |

 

 

E-4

----
CERTIFICATIONS

Exhibit 31.1



I, Gregory F. Kowal, certify that:



1.  I have reviewed this quarterly report on Form 10-QSB of Mera Pharmaceuticals, Inc.;



2.  Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;



3.  Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;



4.  The Company's other certifying officers and I, are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and have:



a)

designed such disclosure controls and procedures to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;



b)

evaluated the effectiveness of the Company's disclosure controls and procedures as of a date within 90 days prior to the filing date of this quarterly report (the "Evaluation Date"); and



c)

presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;



5.  The Company's other certifying officers and I have disclosed, based on our most recent evaluation, to the Company's auditors and the audit committee of Company's board of directors (or persons performing the equivalent functions):



a)

all significant deficiencies in the design or operation of internal controls which could adversely affect the Companys ability to record, process, summarize and report financial data and have identified for the Company's auditors any material weaknesses in internal controls; and



b)

any fraud, whether or not material, that involves management or other employees who have a significant role in the Company's internal controls; and



6.  The Company's other certifying officers and I have indicated in this quarterly report whether there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.



|                        |  | 
|----------------------- |  | 
|Date:   June 11, 2009   |  | 
|                        |  | 
|/s/ GREGORY F. KOWAL    |  | 
|Gregory F. Kowal        |  | 
|Chief Executive Officer |  |
Exhibit 32.2



CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



In connection with the Quarterly Report on Form 10-Q/A of Aphton
Corporation (the Company) for the period ended June 30, 2005 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, James F. Smith, Senior Vice President and Chief Financial Officer of the
Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:



| | (1) | the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
| | --- | ---------------------------------------------------------------------------------------------------------------------------------



| | (2) | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| | --- | ----------------------------------------------------------------------------------------------------------------------------------------------------



|                        |  |     |  |                                                  
|----------------------- |  | --- |  | -------------------------------------------------
|Date: November 23, 2005 |  | By: |  | /s/ James F. Smith                               
|                        |  |     |  | James F. Smith                                   
|                        |  |     |  | Senior Vice President and Chief Financial Officer
|                        |  |     |  | (Principal Financial Officer)
No. 87-1476.

#### Snead et al. *v.*City of Albuquerque.

C. A. 10th Cir. Certiorari denied.
EXHIBIT 31.1
                                  CERTIFICATION

I, John V. Winfield, certify that:

1.  I have reviewed this annual report on Form 10-KSB of The InterGroup
Corporation

2.  Based on my knowledge, this report does not contain any untrue statement of
a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this report;

3.  Based on my knowledge, the financial statements and other financial
information included in this report, fairly present in all material respects
the financial condition, results of operations and cash flows of the registrant
as of, and for, the periods presented in this report;

4.  The registrant's other certifying officer(s) and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

    a) designed such disclosure controls and procedures, or caused such
disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being prepared;

    b) evaluated the effectiveness of the registrant's disclosure controls and
procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered
by this report based on such evaluation; and

    c) disclosed in this report any change in the registrant's internal control
over financial reporting that occurred during the registrant's most recent
fiscal quarter that has materially affected, or is reasonably likely to
materially affect, the registrant's internal control over financial reporting;
and

5.  The registrant's other certifying officer(s) and I have disclosed, based on
our most recent evaluation of internal control over financial reporting, to the
registrant's auditors and the audit committee of registrant's board of
directors (or persons performing equivalent functions):

    a) all significant deficiencies and material weakness in the design or
operation of internal control over financial reporting which are reasonably
likely to adversely affect the registrant's ability to record, process,
summarize and report financial information; and

    b) any fraud, whether or not material, that involves management or other
employees who have a significant role in registrant's internal control over
financial reporting.

Date: September 28, 2007                      /s/ John V. Winfield
                                              ---------------------------
                                              John V. Winfield, President
                                              and Chief Executive Officer
IN THE UNITED STATES DISTRICT COURT FOR THE 

SOUTHERN DISTRICT OF ALABAMA

SOUTHERN DIVISION

ALFONSO BLACKMON, a/k/a, :

YAHYA R. EL’AMIN, a/k/a, 

JOHN THOMPKINS, :

Plaintiff, :

vs. : CIVIL ACTION 05-0316-BH-D

SHERIFF JIMMY JOHNSON, et al., :

Defendants. :

JUDGMENT

It is ORDERED, ADJUDGED, and DECREED that defendants Allen Perdue, Jonathan

Armstrong, Frank Burt, Jr., George Price, Mary Frances Stewart, Charles A. Browdy, and Joe T.

Faust be DISMISSED from this action with prejudice, prior to service of process, pursuant to 28

U.S.C. § 1915(e)(2)(B)(i), as the claims against them are frivolous; that, based on the abstention

principles of Younger v. Harris, 401 U.S. 37, 91 S.Ct. 746, 27 L.Ed.2d 669 (1971), the claims for

injunctive and declaratory relief be DISMISSED; and that the damages claims be STAYED

until the criminal proceedings against plaintiff are concluded. 

DONE this 29th day of March, 2006.

 s/ W. B. Hand 

 SENIOR DISTRICT JUDGE 

Case 1:05-cv-00316-CG-B Document 15 Filed 03/29/06 Page 1 of 1
IN THE UNITED STATES DISTRICT COURT

FOR THE SOUTHERN DISTRICT OF ALABAMA

SOUTHERN DIVISION

SAUL THOMAS TAYLOR, )

Plaintiff, )

vs. ) Civil Action No. 10-0032-KD-B

DEPARTMENT OF HUMAN )

RESOURCES and CHILD SUPPORT, 

et al., )

Defendants. )

ORDER

After due and proper consideration of all portions of this file deemed relevant to the

issues raised, and there having been no objections filed, the recommendation of the Magistrate

Judge made under 28 U.S.C. § 636(b)(l)(B) and dated February 26, 2010, is ADOPTED as the

opinion of this Court.

DONE this March 16, 2010.

s/ Kristi K. DuBose

KRISTI K. DuBOSE 

UNITED STATES DISTRICT JUDGE

Case 1:10-cv-00032-KD-B Document 6 Filed 03/16/10 Page 1 of 1
<PAGE>
                                                                   EXHIBIT 32.02

                CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


      In connection with the Annual Report on Form 10-K of Nashua Corporation
(the "Company") for the period ended December 31, 2003 as filed with the
Securities and Exchange Commission on the date hereof (the "Report"), the
undersigned, John L. Patenaude, Vice President-Finance and Chief Financial
Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350,
that:

            (1)   the Report fully complies with the requirements of Section
      13(a) or 15(d) of the Securities Exchange Act of 1934; and

            (2) the information contained in the Report fairly presents, in all
      material respects, the financial condition and results of operations of
      the Company.

                                          /s/ John L. Patenaude
                                          ------------------------------------
Dated:  March 15, 2004                    John L. Patenaude
        ------------------                Vice President-Finance and
                                          Chief Financial Officer
I 

118TH CONGRESS 

1ST SESSION H. R. 1497 

To provide that, for a 3-year period, applications for the exportation of 

natural gas to member countries of the North Atlantic Treaty Organization be granted without modification or delay, and for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

MARCH 9, 2023 

Mrs. FLETCHER introduced the following bill; which was referred to the 

Committee on Energy and Commerce 

A BILL 

To provide that, for a 3-year period, applications for the 

exportation of natural gas to member countries of the 

North Atlantic Treaty Organization be granted without 

modification or delay, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘American Gas for Al5 lies Act’’. 


kjohnson on DSK79L0C42PROD with BILLS
2 

•HR 1497 IH

1 SEC. 2. TEMPORARY TREATMENT OF CERTAIN APPLICA2 TIONS FOR THE EXPORTATION OF NATURAL 

3 GAS. 

4 (a) IN GENERAL.—During the period described in 

5 subsection (c) of this section, for purposes of section 3(a) 

6 of the Natural Gas Act (15 U.S.C. 717b(a)), the expor7 tation of natural gas to a foreign country described in sub8 section (b) of this section shall be deemed to be consistent 

9 with the public interest, and applications for such expor10 tation shall be granted without modification or delay. 

11 (b) FOREIGN COUNTRIES.—A foreign country de12 scribed in this subsection is— 

13 (1) a member country of the North Atlantic 

14 Treaty Organization; or 

15 (2) any other foreign country, if the Secretary 

16 of State, in consultation with the Secretary of De17 fense and the Secretary of Energy, determines that 

18 exportation of natural gas to that foreign country 

19 would promote the national security interests of the 

20 United States. 

21 (c) APPLICABILITY.—This section shall apply with re22 spect to applications for the authorization to export nat23 ural gas under section 3 of the Natural Gas Act (15 

24 U.S.C. 717b) to a foreign country described in subsection 

25 (b) of this section that are pending on the date of enact26 ment of this Act, or filed during the period that begins 


kjohnson on DSK79L0C42PROD with BILLS
3 

•HR 1497 IH

1 on such date of enactment and ends on the date that is 

2 3 years after such date of enactment. 

Æ 


kjohnson on DSK79L0C42PROD with BILLS
MODERN CONTROLS, INC.

                    COMPUTATION OF PER SHARE EARNINGS




                                                                         
                                            Years ended December 31
                                  ------------------------------------
                                        1995         1994         1993
                                  ------------------------------------
PRIMARY

Average shares outstanding         4,527,560    4,722,188    4,851,565

Net effect of dilutive stock
  options - based on the
  treasury stock method               20,843        3,422       26,261
                                  ----------   ----------   ----------
Total                              4,548,403    4,725,610    4,877,826
                                  ==========   ==========   ==========

Net income                        $2,570,308   $1,852,977   $1,889,243
                                  ==========   ==========   ==========

Primary per share amounts         $     0.57   $     0.39   $     0.39
                                  ==========   ==========   ==========

FULLY DILUTED

Average shares outstanding         4,527,560    4,722,188    4,851,565

Net effect of dilutive stock
  options - based on the
  treasury stock method               25,640        1,995       24,538
                                  ----------   ----------   ----------
Total                              4,553,200    4,724,183    4,876,103
                                  ==========   ==========   ==========

Net income                        $2,570,308   $1,852,977   $1,889,243
                                  ==========   ==========   ==========

Fully diluted per share amounts   $     0.56   $     0.39   $     0.39
                                  ==========   ==========   ==========